Immunocore (NASDAQ:IMCR – Get Free Report) and Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation.
Profitability
This table compares Immunocore and Scinai Immunotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Immunocore | -15.87% | -12.84% | -5.09% |
| Scinai Immunotherapeutics | N/A | N/A | -30.48% |
Institutional & Insider Ownership
84.5% of Immunocore shares are held by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are held by institutional investors. 9.1% of Immunocore shares are held by company insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Immunocore | $310.20 million | 4.34 | -$55.29 million | ($1.02) | -26.39 |
| Scinai Immunotherapeutics | $452,000.00 | 4.13 | -$6.50 million | ($239.17) | -0.01 |
Scinai Immunotherapeutics has lower revenue, but higher earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Immunocore has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.68, suggesting that its share price is 168% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and price targets for Immunocore and Scinai Immunotherapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Immunocore | 1 | 4 | 8 | 0 | 2.54 |
| Scinai Immunotherapeutics | 0 | 0 | 0 | 0 | 0.00 |
Immunocore currently has a consensus price target of $63.73, indicating a potential upside of 136.73%. Given Immunocore’s stronger consensus rating and higher possible upside, equities analysts clearly believe Immunocore is more favorable than Scinai Immunotherapeutics.
Summary
Immunocore beats Scinai Immunotherapeutics on 8 of the 14 factors compared between the two stocks.
About Immunocore
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company’s product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.
